HC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9
Cardiol Therapeutics Inc Ordinary Shares - Class A -2.09%
Cardiol Therapeutics Inc Ordinary Shares - Class A CRDL | 1.87 | -2.09% |
HC Wainwright & Co. analyst Vernon Bernardino initiates coverage on Cardiol Therapeutics (NASDAQ:
CRDL) with a Buy rating and announces Price Target of $9.